Active Not Recruiting PHASE1 INTERVENTIONAL 10-arm NCT07170319

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After Multiple Ascending Doses in Participants With Overweight or Obesity

Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

Conditions Overweight or Obesity

Interventions IBI3032 placebo

Updated 2 times since 2025 Last updated: Dec 29, 2025 Started: Sep 25, 2025 Primary completion: Dec 24, 2025 Completion: Mar 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Overweight or Obesity, this trial is ongoing. The trial is conducted by Innovent Biologics Technology Limited (Shanghai R&D Center) and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Jan 2026 — Present [monthly]

Active Not Recruiting PHASE1

Status: Not Yet Recruiting → Active Not Recruiting
Oct 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE1

First recorded

Sep 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Innovent Biologics Technology Limited (Shanghai R&D Center)

Data source: Innovent Biologics Technology Limited (Shanghai R&D Center)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hefei, China